Combination of HDAC and topoisomerase inhibitors in small cell lung cancer

References

• Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010; 60:277 - 300; http://dx.doi.org/10.3322/caac.20073; PMID: 20610543
   PubMed Web of Science ®Google Scholar
• Jänne PA, Freidlin B, Saxman S, Johnson DH, Livingston RB, Shepherd FA, et al. Twenty-five years of clinical research for patients with limited-stage small cell lung carcinoma in North America. Cancer 2002; 95:1528 - 38; http://dx.doi.org/10.1002/cncr.10841; PMID: 12237922
   PubMed Web of Science ®Google Scholar
• Simon GR, Wagner H, American College of Chest Physicians. Small cell lung cancer. Chest 2003; 123:Suppl 259S - 71S; http://dx.doi.org/10.1378/chest.123.1_suppl.259S; PMID: 12527584
   PubMed Web of Science ®Google Scholar
• Davies AM, Lara PN, Lau DH, Gandara DR. Treatment of extensive small cell lung cancer. Hematol Oncol Clin North Am 2004; 18:373 - 85; http://dx.doi.org/10.1016/j.hoc.2003.12.012; PMID: 15094177
   PubMed Web of Science ®Google Scholar
• Ardizzoni A, Hansen H, Dombernowsky P, Gamucci T, Kaplan S, Postmus P, et al. Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and New Drug Development Office, and the Lung Cancer Cooperative Group. J Clin Oncol 1997; 15:2090 - 6; PMID: 9164222
   PubMed Web of Science ®Google Scholar
• von Pawel J, Schiller JH, Shepherd FA, Fields SZ, Kleisbauer JP, Chrysson NG, et al. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol 1999; 17:658 - 67; PMID: 10080612
   PubMed Web of Science ®Google Scholar
• O’Brien ME, Ciuleanu TE, Tsekov H, Shparyk Y, Cuceviá B, Juhasz G, et al. Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer. J Clin Oncol 2006; 24:5441 - 7; http://dx.doi.org/10.1200/JCO.2006.06.5821; PMID: 17135646
   PubMed Web of Science ®Google Scholar
• Onoda S, Masuda N, Seto T, Eguchi K, Takiguchi Y, Isobe H, et al, Thoracic Oncology Research Group Study 0301. Phase II trial of amrubicin for treatment of refractory or relapsed small-cell lung cancer: Thoracic Oncology Research Group Study 0301. J Clin Oncol 2006; 24:5448 - 53; http://dx.doi.org/10.1200/JCO.2006.08.4145; PMID: 17135647
   PubMed Web of Science ®Google Scholar
• Ettinger DS, Jotte R, Lorigan P, Gupta V, Garbo L, Alemany C, et al. Phase II study of amrubicin as second-line therapy in patients with platinum-refractory small-cell lung cancer. J Clin Oncol 2010; 28:2598 - 603; http://dx.doi.org/10.1200/JCO.2009.26.7682; PMID: 20385980
   PubMed Web of Science ®Google Scholar
• Jotte R, Conkling P, Reynolds C, Galsky MD, Klein L, Fitzgibbons JF, et al. Randomized phase II trial of single-agent amrubicin or topotecan as second-line treatment in patients with small-cell lung cancer sensitive to first-line platinum-based chemotherapy. J Clin Oncol 2011; 29:287 - 93; http://dx.doi.org/10.1200/JCO.2010.29.8851; PMID: 21135284
   PubMed Web of Science ®Google Scholar
• Inoue A, Sugawara S, Yamazaki K, Maemondo M, Suzuki T, Gomi K, et al. Randomized phase II trial comparing amrubicin with topotecan in patients with previously treated small-cell lung cancer: North Japan Lung Cancer Study Group Trial 0402. J Clin Oncol 2008; 26:5401 - 6; http://dx.doi.org/10.1200/JCO.2008.18.1974; PMID: 18854562
   PubMed Web of Science ®Google Scholar
• Pommier Y. DNA topoisomerase I inhibitors: chemistry, biology, and interfacial inhibition. Chem Rev 2009; 109:2894 - 902; http://dx.doi.org/10.1021/cr900097c; PMID: 19476377
   PubMed Web of Science ®Google Scholar
• Pommier Y, Pourquier P, Urasaki Y, Wu J, Laco GS. Topoisomerase I inhibitors: selectivity and cellular resistance. Drug Resist Updat 1999; 2:307 - 18; http://dx.doi.org/10.1054/drup.1999.0102; PMID: 11504505
   PubMed Web of Science ®Google Scholar
• Brangi M, Litman T, Ciotti M, Nishiyama K, Kohlhagen G, Takimoto C, et al. Camptothecin resistance: role of the ATP-binding cassette (ABC), mitoxantrone-resistance half-transporter (MXR), and potential for glucuronidation in MXR-expressing cells. Cancer Res 1999; 59:5938 - 46; PMID: 10606239
   PubMed Web of Science ®Google Scholar
• Bates SE, Medina-Pérez WY, Kohlhagen G, Antony S, Nadjem T, Robey RW, et al. ABCG2 mediates differential resistance to SN-38 (7-ethyl-10-hydroxycamptothecin) and homocamptothecins. J Pharmacol Exp Ther 2004; 310:836 - 42; http://dx.doi.org/10.1124/jpet.103.063149; PMID: 15075385
   PubMed Web of Science ®Google Scholar
• Liao Z, Robey RW, Guirouilh-Barbat J, To KK, Polgar O, Bates SE, et al. Reduced expression of DNA topoisomerase I in SF295 human glioblastoma cells selected for resistance to homocamptothecin and diflomotecan. Mol Pharmacol 2008; 73:490 - 7; http://dx.doi.org/10.1124/mol.107.041178; PMID: 17984197
   PubMed Web of Science ®Google Scholar
• Glozak MA, Sengupta N, Zhang X, Seto E. Acetylation and deacetylation of non-histone proteins. Gene 2005; 363:15 - 23; http://dx.doi.org/10.1016/j.gene.2005.09.010; PMID: 16289629
   PubMed Web of Science ®Google Scholar
• Kim SC Sr., Sprung R, Chen Y, Xu Y, Ball H, Pei J, et al. Substrate and functional diversity of lysine acetylation revealed by a proteomics survey. Mol Cell 2006; 23:607 - 18; http://dx.doi.org/10.1016/j.molcel.2006.06.026; PMID: 16916647
   PubMed Web of Science ®Google Scholar
• Nimmanapalli R, Fuino L, Bali P, Gasparetto M, Glozak M, Tao J, et al. Histone deacetylase inhibitor LAQ824 both lowers expression and promotes proteasomal degradation of Bcr-Abl and induces apoptosis of imatinib mesylate-sensitive or -refractory chronic myelogenous leukemia-blast crisis cells. Cancer Res 2003; 63:5126 - 35; PMID: 12941844
   PubMed Web of Science ®Google Scholar
• Garcia-Manero G, Assouline S, Cortes J, Estrov Z, Kantarjian H, Yang H, et al. Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia. Blood 2008; 112:981 - 9; http://dx.doi.org/10.1182/blood-2007-10-115873; PMID: 18495956
   PubMed Web of Science ®Google Scholar
• Stimson L, Wood V, Khan O, Fotheringham S, La Thangue NB. HDAC inhibitor-based therapies and haematological malignancy. Ann Oncol 2009; 20:1293 - 302; http://dx.doi.org/10.1093/annonc/mdn792; PMID: 19515748
   PubMed Web of Science ®Google Scholar
• Fazzone W, Wilson PM, Labonte MJ, Lenz H-J, Ladner RD. Histone deacetylase inhibitors suppress thymidylate synthase gene expression and synergize with the fluoropyrimidines in colon cancer cells. Int J Cancer 2009; 125:463 - 73; PMID: 19384949
   PubMed Web of Science ®Google Scholar
• Li Z, Zhou N, Fournel M, et al. Antitumor Activities of MGCD0103, a novel and isotype-selective histone deacetylase inhibitor. Eur J Cancer Supp Mol Targets Cancer Ther 2004; 2:Abstract 83
   Google Scholar
• Moradei O, Leit S, Zhou N, Fréchette S, Paquin I, Raeppel S, et al. Substituted N-(2-aminophenyl)-benzamides, (E)-N-(2-aminophenyl)-acrylamides and their analogues: novel classes of histone deacetylase inhibitors. Bioorg Med Chem Lett 2006; 16:4048 - 52; http://dx.doi.org/10.1016/j.bmcl.2006.05.005; PMID: 16713259
   PubMed Web of Science ®Google Scholar
• Siu LL, Pili R, Duran I, Messersmith WA, Chen EX, Sullivan R, et al. Phase I study of MGCD0103 given as a three-times-per-week oral dose in patients with advanced solid tumors. J Clin Oncol 2008; 26:1940 - 7; http://dx.doi.org/10.1200/JCO.2007.14.5730; PMID: 18421048
   PubMed Web of Science ®Google Scholar
• Marchion DC, Bicaku E, Turner JG, Daud AI, Sullivan DM, Munster PN. Synergistic interaction between histone deacetylase and topoisomerase II inhibitors is mediated through topoisomerase IIbeta. Clin Cancer Res 2005; 11:8467 - 75; http://dx.doi.org/10.1158/1078-0432.CCR-05-1073; PMID: 16322310
   PubMed Web of Science ®Google Scholar
• Münster P, Marchion D, Bicaku E, Schmitt M, Lee JH, DeConti R, et al. Phase I trial of histone deacetylase inhibition by valproic acid followed by the topoisomerase II inhibitor epirubicin in advanced solid tumors: a clinical and translational study. J Clin Oncol 2007; 25:1979 - 85; http://dx.doi.org/10.1200/JCO.2006.08.6165; PMID: 17513804
   PubMed Web of Science ®Google Scholar
• Yoshida M, Kijima M, Akita M, Beppu T. Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A. J Biol Chem 1990; 265:17174 - 9; PMID: 2211619
   PubMed Web of Science ®Google Scholar
• Johnson CA, Padget K, Austin CA, Turner BM. Deacetylase activity associates with topoisomerase II and is necessary for etoposide-induced apoptosis. J Biol Chem 2001; 276:4539 - 42; http://dx.doi.org/10.1074/jbc.C000824200; PMID: 11136718
   PubMed Web of Science ®Google Scholar
• Bevins RL, Zimmer SG. It’s about time: scheduling alters effect of histone deacetylase inhibitors on camptothecin-treated cells. Cancer Res 2005; 65:6957 - 66; http://dx.doi.org/10.1158/0008-5472.CAN-05-0836; PMID: 16061681
   PubMed Web of Science ®Google Scholar
• Tsai SC, Valkov N, Yang WM, Gump J, Sullivan D, Seto E. Histone deacetylase interacts directly with DNA topoisomerase II. Nat Genet 2000; 26:349 - 53; http://dx.doi.org/10.1038/81671; PMID: 11062478
   PubMed Web of Science ®Google Scholar
• Catalano MG, Fortunati N, Pugliese M, Poli R, Bosco O, Mastrocola R, et al. Valproic acid, a histone deacetylase inhibitor, enhances sensitivity to doxorubicin in anaplastic thyroid cancer cells. J Endocrinol 2006; 191:465 - 72; http://dx.doi.org/10.1677/joe.1.06970; PMID: 17088416
   PubMed Web of Science ®Google Scholar
• Marchion DC, Bicaku E, Daud AI, Richon V, Sullivan DM, Munster PN. Sequence-specific potentiation of topoisomerase II inhibitors by the histone deacetylase inhibitor suberoylanilide hydroxamic acid. J Cell Biochem 2004; 92:223 - 37; http://dx.doi.org/10.1002/jcb.20045; PMID: 15108350
   PubMed Web of Science ®Google Scholar
• Marchion DC, Bicaku E, Turner JG, Schmitt ML, Morelli DR, Munster PN. HDAC2 regulates chromatin plasticity and enhances DNA vulnerability. Mol Cancer Ther 2009; 8:794 - 801; http://dx.doi.org/10.1158/1535-7163.MCT-08-0985; PMID: 19372552
   PubMed Web of Science ®Google Scholar
• Bruzzese F, Rocco M, Castelli S, Di Gennaro E, Desideri A, Budillon A. Synergistic antitumor effect between vorinostat and topotecan in small cell lung cancer cells is mediated by generation of reactive oxygen species and DNA damage-induced apoptosis. Mol Cancer Ther 2009; 8:3075 - 87; http://dx.doi.org/10.1158/1535-7163.MCT-09-0254; PMID: 19887547
   PubMed Web of Science ®Google Scholar
• Dedes KJ, Dedes I, Imesch P, von Bueren AO, Fink D, Fedier A. Acquired vorinostat resistance shows partial cross-resistance to ‘second-generation’ HDAC inhibitors and correlates with loss of histone acetylation and apoptosis but not with altered HDAC and HAT activities. Anticancer Drugs 2009; 20:321 - 33; http://dx.doi.org/10.1097/CAD.0b013e3283262a32; PMID: 19322073
   PubMed Web of Science ®Google Scholar
• Bhalla KN. Epigenetic and chromatin modifiers as targeted therapy of hematologic malignancies. J Clin Oncol 2005; 23:3971 - 93; http://dx.doi.org/10.1200/JCO.2005.16.600; PMID: 15897549
   PubMed Web of Science ®Google Scholar
• Gu W, Roeder RG. Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. Cell 1997; 90:595 - 606; PMID: 9288740
   PubMed Web of Science ®Google Scholar
• Kim MS, Blake M, Baek JH, Kohlhagen G, Pommier Y, Carrier F. Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA. Cancer Res 2003; 63:7291 - 300; PMID: 14612526
   PubMed Web of Science ®Google Scholar
• Piacentini P, Donadelli M, Costanzo C, Moore PS, Palmieri M, Scarpa A. Trichostatin A enhances the response of chemotherapeutic agents in inhibiting pancreatic cancer cell proliferation. Virchows Arch 2006; 448:797 - 804; http://dx.doi.org/10.1007/s00428-006-0173-x; PMID: 16568310
   PubMed Web of Science ®Google Scholar
• Nolan L, Johnson PW, Ganesan A, Packham G, Crabb SJ. Will histone deacetylase inhibitors require combination with other agents to fulfil their therapeutic potential?. Br J Cancer 2008; 99:689 - 94; http://dx.doi.org/10.1038/sj.bjc.6604557; PMID: 18728657
   PubMed Web of Science ®Google Scholar
• Chou T, ed. The median-effect principle and the combination index for quantitation of synergism and antagonism. San Diego: Academic Press; 1991.
   Google Scholar
• Chou T-C. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 2006; 58:621 - 81; http://dx.doi.org/10.1124/pr.58.3.10; PMID: 16968952
   PubMed Web of Science ®Google Scholar